key: cord-0723142-3h7fjhod authors: Schroeder, B.A.; Cuevas, E.; Graber, J.J. title: Multidisciplinary tumor boards present technical and financial challenges in the COVID-19 era date: 2021-03-16 journal: Ann Oncol DOI: 10.1016/j.annonc.2021.03.004 sha: c74c8324f023ec2b0517bed46add57e85601cdbd doc_id: 723142 cord_uid: 3h7fjhod nan Multidisciplinary tumor boards present technical and financial challenges in the COVID-19 era We read with interest the commentary by Gross et al. 1 regarding multidisciplinary tumor (MDT) boards as videoconferences during the coronavirus disease 2019 (COVID-19) pandemic. Of note, the authors mention that MDT performance is variable and dependent on several factors including clinical inputs, radiology, pathology, and meeting management. 2 Videoconference tumor boards may become more common due to mitigation of travel time, easier involvement for multiple specialists, and ability to share comprehensive diagnostic data among participants. However, we would add that these MDTs are not without substantial financial costs. We utilized available salary data for physicians, mid-level providers, and registered nurses. 3 Published average hours for various health care providers were used to calculate hourly wages, and collectively, these data were used to estimate mean costs per MDT, as well as annual costs for MDTs across nine subspecialties at a single academic center. We found that the estimated annual cost of these nine tumor board meetings was $648 182.52 for physician compensation, and $797 667.56 annually for all providers (Table 1) . We agree with Gross and others that in oncology, MDT boards are a commonly promoted practice in management and decision making for the complex care of cancer patients. 4 However, it is important to recognize that technical issues, participant issues, and limitations affecting the interactions among decision makers can pose challenges, which could have negative implications for patient outcomes. Therefore, the introduction of videoconferences in routine MDT boards could benefit from standardized procedures, and as the authors suggest, distribution of these regulations among attendees could improve efficiency while simultaneously bolstering patient-centered care and reducing related financial costs. Volume xxx -Issue --2021 1 Multidisciplinary tumor boards as videoconferencesda new challenge in the COVID-19 era The anatomy of clinical decisionmaking in the multidisciplinary cancer meetings. A cross-sectional observational study of teams in a natural context Estimated physician cost of a neuro-oncology multidisciplinary team tumor board meeting at a single academic center Multidisciplinary teams in cancer care: are they effective in the UK?